Business
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
Company to Host Conference Call Today, May 7th, at 4:30pm ETBOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2026 and provides a business update. Q1 2026 Recent Highlights: CORDStrom™ Platform: Completed a pre-submission package with the United
About this update from Inmune Bio Inc.
[{"type":"image","alt":"INmune Bio, Inc.","displaySize":"","headline":null,"caption":"INmune Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_RfkNrUuo7An1sANp.xPfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_RfkNrUuo7An1sANp.xPfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgw/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60}},"lazy":false},{"type":"text","content":"Company to Host Conference Call Today, May 7th, at 4:30pm ET","length":60,"tagName":"p"},{"type":"text","content":"BOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2026 and provides a business update.","length":345,"tagName":"p"},{"type":"text","content":"Q1 2026 Recent Highlights:","length":36,"tagName":"p"},{"type":"text","content":"CORDStrom™ Platform:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Completed a pre-submission package with the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). The CORDStrom™ program in recessive dystrophic epidermolysis bullosa (RDEB) is on target to file an MAA submission in the UK mid-summer, followed shortly thereafter by anticipated EMA and FDA regulatory submissions.","length":336,"tagName":"p"}]},{"val":[{"type":"text","content":"Signed an amended and restated Material Transfer and License Agreement with Anthony Nolan. This expanded strategic collaboration secures the long-term, reliable supply of high-quality umbilical cord tissue from their world-class cord blood bank to fuel our CORDStrom™ platform.","length":277,"tagName":"p"}]},{"val":[{"type":"text","content":"Hosted KOL led webinar focused on the latest results from the MissionEB Phase III clinical trial highlighting the systemic disease-modifying capabilities of CORDStrom™ in patients...